Dr. Abi Siva & Dr. Carey Anders - DESTINY-Breast05, DESTINY- Breast11 and T-DXd Integration

Community Health Media · Jun 25, 2026 · 37m

How is T-DXd reshaping treatment for patients with early-stage HER2-positive breast cancer

Dr. Abi Siva and Dr. Carey Anders discuss the evolving role of T-DXd across the treatment continuum, including the latest data from DESTINY-Breast11 and DESTINY-Breast05. The conversation explores how these studies are influencing neoadjuvant and adjuvant treatment strategies, patient selection, toxicity management, and future sequencing decisions.

The experts examine key clinical questions surrounding pCR, residual disease management, ILD monitoring, radiation considerations, treatment duration…